Structure-guided discovery of a single-domain antibody agonist against human apelin receptor.

Sci Adv

Amgen Discovery Research, Amgen Asia R&D Center, Amgen Biopharmaceutical R&D (Shanghai) Co. Ltd., 13th Floor, Building No. 2, 4560 Jinke Road, Zhangjiang, Shanghai 201210, China.

Published: January 2020

Developing antibody agonists targeting the human apelin receptor (APJ) is a promising therapeutic approach for the treatment of chronic heart failure. Here, we report the structure-guided discovery of a single-domain antibody (sdAb) agonist JN241-9, based on the cocrystal structure of APJ with an sdAb antagonist JN241, the first cocrystal structure of a class A G protein-coupled receptor (GPCR) with a functional antibody. As revealed by the structure, JN241 binds to the extracellular side of APJ, makes critical contacts with the second extracellular loop, and inserts the CDR3 into the ligand-binding pocket. We converted JN241 into a full agonist JN241-9 by inserting a tyrosine into the CDR3. Modeling and molecular dynamics simulation shed light on JN241-9-stimulated receptor activation, providing structural insights for finding agonistic antibodies against class A GPCRs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962038PMC
http://dx.doi.org/10.1126/sciadv.aax7379DOI Listing

Publication Analysis

Top Keywords

structure-guided discovery
8
discovery single-domain
8
single-domain antibody
8
human apelin
8
apelin receptor
8
agonist jn241-9
8
cocrystal structure
8
antibody
4
antibody agonist
4
agonist human
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!